Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. MAIT cell subtypes in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inflammatory markers of CHMP2B-mediated frontotemporal dementia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

OriginalsprogEngelsk
TidsskriftJournal of Neuroimmunology
Vol/bind337
Sider (fra-til)577085
ISSN0165-5728
DOI
StatusUdgivet - 15 dec. 2019

Bibliografisk note

Copyright © 2019 Elsevier B.V. All rights reserved.

ID: 61518900